ClinicaliQ Trial Snapshot
- A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy — Active Not Recruiting • Phase III • Oncology • NCT04873362.
- Adding immunotherapy to standard HER2 treatment reduces breast cancer recurrence risk in patients with residual disease after pre-surgery therapy.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants. Conditions: Breast Cancer Interventions: Atezolizumab, Trastuzumab Emtansine, Placebo, Trastuzumab Lead Sponsor: Hoffmann-La Roche Planned Enrollment: 1188 participants